Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization

Aim:  We reported previously that hypoadiponectinemia enhances hepatic oxidative stress and accelerates progression of nonalcoholic steatohepatitis (NASH) in mice. However, the precise mechanism and preventive effects of adiponectin on NASH remain unclear. The aim of this study was to examine the effects of adiponectin on steatohepatitis using adiponectin‐knockout (KO) mice and adenovirus‐mediated adiponectin expression system.

[1]  M. Gambardella,et al.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.

[2]  S. Kihara,et al.  Adiponectin deficiency exacerbates lipopolysaccharide/D-galactosamine-induced liver injury in mice. , 2006, World journal of gastroenterology.

[3]  J. George,et al.  Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity? , 2002, Hepatology.

[4]  A. Greenberg,et al.  Obesity and the role of adipose tissue in inflammation and metabolism. , 2006, The American journal of clinical nutrition.

[5]  M. Matsuda,et al.  Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. , 2003, Diabetes.

[6]  J. Friedman,et al.  Obesity in the new millennium , 2000, Nature.

[7]  H. Lodish,et al.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Kohjiro Ueki,et al.  Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. , 2006, The Journal of clinical investigation.

[9]  M. Matsuda,et al.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 , 2002, Nature Medicine.

[10]  S. Kihara,et al.  Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. , 2007, Journal of hepatology.

[11]  T. Funahashi,et al.  Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[12]  P. Giral,et al.  Liver fibrosis in overweight patients. , 2000, Gastroenterology.

[13]  Yu Wang,et al.  The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. , 2003, The Journal of clinical investigation.

[14]  E. Brunt.  Nonalcoholic Steatohepatitis: Definition and Pathology , 2001, Seminars in liver disease.

[15]  M. Makuuchi,et al.  Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans. , 2001, Biochemical and biophysical research communications.

[16]  J. Yodoi,et al.  Control of oxidative stress and reduction in biochemical markers by Vitamin E treatment in patients with nonalcoholic steatohepatitis: a pilot study. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[17]  S. Kihara,et al.  Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. , 2000, Blood.

[18]  B. Spiegelman,et al.  Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link , 1994, Diabetes.

[19]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[20]  S. Kihara,et al.  Adiponectin Specifically Increased Tissue Inhibitor of Metalloproteinase-1 Through Interleukin-10 Expression in Human Macrophages , 2004, Circulation.

[21]  H. Motoshima,et al.  Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. , 2004, Biochemical and biophysical research communications.

[22]  S. Yamashita,et al.  Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty , 1996, Nature Medicine.

[23]  J. Crespo,et al.  Gene expression of tumor necrosis factor α and TNF‐receptors, p55 and p75, in nonalcoholic steatohepatitis patients , 2001 .

[24]  Takashi Kadowaki,et al.  Combination , 2019, Understanding the Law of Assignment.

[25]  M. Yalnız,et al.  Serum Adipokine and Ghrelin Levels in Nonalcoholic Steatohepatitis , 2006, Mediators of inflammation.

[26]  A. Saltiel,et al.  Obesity induces a phenotypic switch in adipose tissue macrophage polarization. , 2007, The Journal of clinical investigation.

[27]  Mauro Salizzoni,et al.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.

[28]  S. Kihara,et al.  Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. , 2003, Gastroenterology.

[29]  J. Pascussi,et al.  Cytoprotective properties of alpha-tocopherol are related to gene regulation in cultured D-galactosamine-treated human hepatocytes. , 2007, Free radical biology & medicine.

[30]  F. Capron,et al.  Excess weight risk factor for alcoholic liver disease , 1997, Hepatology.

[31]  J. Lavine.  Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. , 2000, The Journal of pediatrics.

[32]  A. Diehl,et al.  Animal Models of Steatosis , 2001, Seminars in liver disease.

[33]  Y. Matsuzawa.  The metabolic syndrome and adipocytokines , 2006, Expert review of clinical immunology.

[34]  Z. Bloomgarden,et al.  Inflammation and insulin resistance. , 2003, Diabetes care.

[35]  Bruce M. Spiegelman,et al.  Obesity and the Regulation of Energy Balance , 2001, Cell.

[36]  原野 雄一.  Fenofibrate, a peroxisome proliferator-activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver , 2006 .

[37]  D A Follmann,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans , 2022 .

[38]  M. Matsuda,et al.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.

[39]  J. Kench,et al.  Beyond insulin resistance in NASH: TNF‐α or adiponectin? , 2004, Hepatology.

[40]  G. Loss,et al.  Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? , 2002, Hepatology.

[41]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[42]  G. Pacini,et al.  Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association , 2002, Hepatology.

[43]  A. Clouston,et al.  Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis , 1999, Hepatology.

[44]  J. Halaas,et al.  Leptin and the regulation of body weight in mammals , 1998, Nature.

[45]  D. Tanné,et al.  Effects of Peroxisome Proliferator-Activated Receptor Ligands, Bezafibrate and Fenofibrate, on Adiponectin Level , 2007, Arteriosclerosis, thrombosis, and vascular biology.